Oragenics Chief Medical Officer to Present at IPAC-RS 2026 Nasal Innovation ForumGlobeNewsWire · Sep 16, 2026
Oragenics Reports Continued Clinical Progress, Provides Regulatory and NYSE American Listing UpdateGlobeNewsWire · Aug 28, 2026
Oragenics (NYSEAMERICAN:OGEN) Trading Up 0.2% – Time to Buy?Defense World · Aug 12, 2026Oragenics, Inc. (OGEN) is a U.S.-based biotechnology firm primarily focused on creating treatments for infectious diseases. Among its pipeline assets are two vaccine candidates designed to combat the novel severe acute respiratory syndrome coronavirus (SARS-CoV-2): NT-CoV2-1, an intranasal formulation, and Terra CoV-2, an intramuscular option. Beyond its infectious disease focus, Oragenics also has other experimental treatments under development, including LPT3-04, targeting weight loss, and SMaRT Replacement Therapy, a topical solution aimed at preventing dental cavities.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 13, 2026 | -$90.00 | -$0.57 | Beat |
| May 8, 2026 | -$90.00 | -$0.51 | Beat |
| Feb 26, 2026 | -$90.00 | -$0.54 | Beat |
| Nov 7, 2025 | -$144.00 | -$1.96 | Beat |
| Aug 8, 2025 | – | -$3.10 | |
| May 9, 2025 | – | -$3.60 |